ZYNERBA PHARMACEUTICALS INC's ticker is ZYNE and the CUSIP is 98986X109. A total of 44 filers reported holding ZYNERBA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,604 | +69.0% | 16,161 | -56.5% | 0.00% | – |
| Q2 2023 | $12,192 | -21.3% | 37,110 | -1.3% | 0.00% | – |
| Q1 2023 | $15,486 | -3.2% | 37,609 | +19.9% | 0.00% | – |
| Q4 2022 | $16,000 | -33.3% | 31,359 | +0.6% | 0.00% | – |
| Q3 2022 | $24,000 | -36.8% | 31,159 | -4.0% | 0.00% | – |
| Q2 2022 | $38,000 | -72.9% | 32,459 | +99.2% | 0.00% | – |
| Q1 2022 | $140,000 | +288.9% | 16,294 | +28.7% | 0.00% | – |
| Q4 2021 | $36,000 | -21.7% | 12,662 | +16.1% | 0.00% | – |
| Q3 2021 | $46,000 | -22.0% | 10,902 | -4.0% | 0.00% | – |
| Q2 2021 | $59,000 | +7.3% | 11,352 | -4.8% | 0.00% | – |
| Q1 2021 | $55,000 | +52.8% | 11,925 | +5.2% | 0.00% | – |
| Q4 2020 | $36,000 | -47.8% | 11,335 | -46.4% | 0.00% | – |
| Q3 2020 | $69,000 | -36.1% | 21,135 | -34.3% | 0.00% | – |
| Q2 2020 | $108,000 | -8.5% | 32,155 | +4.4% | 0.00% | – |
| Q1 2020 | $118,000 | – | 30,786 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Beryl Capital Management LLC | 4,898,927 | $6,246,132 | 0.70% |
| Yakira Capital Management, Inc. | 620,019 | $790,524 | 0.22% |
| Crystalline Management Inc. | 230,817 | $294,292 | 0.21% |
| DELTEC ASSET MANAGEMENT LLC | 475,000 | $605,625 | 0.14% |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 2,283,979 | $2,912,073 | 0.12% |
| PenderFund Capital Management Ltd. | 123,444 | $213 | 0.06% |
| FIFTH LANE CAPITAL, LP | 100,000 | $127,000 | 0.04% |
| CSS LLC/IL | 476,831 | $607,960 | 0.04% |
| Penserra Capital Management LLC | 220,858 | $280 | 0.01% |
| King Wealth Management Group | 16,000 | $20 | 0.00% |